Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

Oral Diseases

Volumn 21, Issue 7, 2015, Pages 899-904

  Ajona, D ^a,b   Pajares, M J ^a,b,c   Chiara, M D ^d   Rodrigo, J P ^d   Jantus Lewintre, E ^e,f   Camps, C ^e,g   Suarez, C ^d   Bagan J V ^g   Montuenga, L M ^a,b,c   Pio, R ^a,b,h  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Recinto de Complejo Hospitalario de Navarra   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^g UNIVERSITY OF VALENCIA   (Spain)

^h UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Biomarker; C4d; Complement system; Diagnosis; Head and neck cancer; Oral cancer; Saliva; Squamous cell carcinoma

Indexed keywords

COMPLEMENT COMPONENT C4D; FOCAL ADHESION KINASE; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SALIVA LEVEL; BLOOD; CANCER STAGING; CHEMISTRY; METABOLISM; MIDDLE AGED; MOUTH TUMOR; OROPHARYNX TUMOR; PATHOLOGY; SALIVA; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; COMPLEMENT C4B; FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PEPTIDE FRAGMENTS; ROC CURVE; SALIVA; TUMOR BURDEN;

EID: 84941744479     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12363     Document Type: Article

References (44)

1. Ajona D, Pajares MJ, Corrales L et al (2013). Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst 105: 1385-1393.
2. Ajona D, Razquin C, Pastor MD et al (2015). Elevated levels of the complement activation product c4d in bronchial fluids for the diagnosis of lung cancer. PLoS ONE 10: e0119878.
3. Arantes LM, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM (2014). Methylation as a biomarker for head and neck cancer. Oral Oncol 50: 587-592.
4. Bagan J, Sarrion G, Jimenez Y (2010). Oral cancer: clinical features. Oral Oncol 46: 414-417.
5. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007). Tongue cancer: is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 65: 229-236.
6. Bjorge L, Hakulinen J, Vintermyr OK et al (2005). Ascitic complement system in ovarian cancer. Br J Cancer 92: 895-905.
7. Blom AM, Osterborg A, Mollnes TE, Okroj M (2015). Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol 66: 164-170.
8. Brailo V, Vucicevic-Boras V, Lukac J et al (2012). Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Med Oral Patol Oral Cir Bucal 17: e10-5.
9. Canel M, Secades P, Rodrigo JP et al (2006). Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res 12: 3272-3279.
10. Canel M, Secades P, Garzon-Arango M et al (2008). Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer 98: 1274-1284.
11. Cheng YS, Rees T, Wright J (2014). A review of research on salivary biomarkers for oral cancer detection. Clin Transl Med 3: 3.
12. Corrales L, Ajona D, Rafail S et al (2012). Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 189: 4674-4683.
13. Franzmann EJ, Reategui EP, Pedroso F et al (2007). Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16: 1348-1355.
14. Hajishengallis G (2010). Complement and periodontitis. Biochem Pharmacol 80: 1992-2001.
15. Hoadley KA, Yau C, Wolf DM et al (2014). Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158: 929-944.
16. Hu S, Arellano M, Boontheung P et al (2008). Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14: 6246-6252.
17. de Jong EP, Xie H, Onsongo G et al (2010). Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS ONE 5: e11148.
18. Kesselring R, Thiel A, Pries R et al (2014). The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. Eur J Cancer 50: 2152-2161.
19. Lingen MW (2010). Screening for oral premalignancy and cancer: what platform and which biomarkers? Cancer Prev Res (Phila) 3: 1056-1059.
20. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW (2012). Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 34: 219-224.
21. Marimuthu A, Chavan S, Sathe G et al (2013). Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta 1834: 2308-2316.
22. Markiewski MM, DeAngelis RA, Benencia F et al (2008). Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235.
23. McCormack SJ, Brazinski SE, Moore JL Jr, Werness BA, Goldstein DJ (1997). Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 15: 265-274.
24. Menendez ST, Rodrigo JP, Alvarez-Teijeiro S et al (2012). Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Mod Pathol 25: 1069-1078.
25. Nitta H, Wada Y, Kawano Y et al (2013). Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res 19: 2004-2013.
26. Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T (2014). Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep 32: 1715-1719.
27. Nunez-Cruz S, Gimotty PA, Guerra MW et al (2012). Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14: 994-1004.
28. Pajares MJ, Agorreta J, Larrayoz M et al (2012). Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30: 1129-1136.
29. Pardoll D (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839.
30. Park NJ, Zhou H, Elashoff D et al (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477.
31. Pio R, Corrales L, Lambris JD (2014). The role of complement in tumor growth. Adv Exp Med Biol 772: 229-262.
32. Polanska H, Raudenska M, Gumulec J et al (2014). Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol 50: 168-177.
33. Prasad G, McCullough M (2013). Chemokines and cytokines as salivary biomarkers for the early diagnosis of oral cancer. Int J Dent 2013: 813756.
34. Ravindranath NM, Shuler C (2006). Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. J Oral Pathol Med 35: 560-567.
35. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F (2005). NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 29: 42-45.
36. Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010). Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797.
37. Rodrigo JP, Heideman DA, Garcia-Pedrero JM et al (2014). Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). Int J Cancer 134: 487-492.
38. Sainger RN, Shah MH, Desai AA et al (2006). Clinical significance of serum p53 antibodies in oral cancer. Tumori 92: 134-139.
39. Vadrevu SK, Chintala NK, Sharma SK et al (2014). Complement C5a receptor facilitates cancer metastasis by altering T cell responses in the metastatic niche. Cancer Res 74: 3454-3465.
40. Vaezi AE, Bepler G, Bhagwat NR et al (2014). Choline phosphate cytidylyltransferase-alpha is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer 120: 1898-1907.
41. van der Waal I (2010). Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol 46: 423-425.
42. Yang Y, Chung EK, Zhou B et al (2003). Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol 171: 2734-2745.
43. Ytting H, Jensenius JC, Christensen IJ, Thiel S, Nielsen HJ (2004). Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 39: 674-679.
44. Zimmermann BG, Wong DT (2008). Salivary mRNA targets for cancer diagnostics. Oral Oncol 44: 425-429.